ArticleTuberculosis (Edinburgh, Scotland)2014
Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis.
Article in Tuberculosis (Edinburgh, Scotland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 90 citations in OpenAlex.
- Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination.Frontiers in immunology · 2023Trial
- BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults.JCI insight · 2019Trial
- Non-Tuberculous Mycobacteria at the Human-Animal-Environment Interface: Antimicrobial Resistance, Environmental Persistence and Cross-Species Exposure Risks.Antibiotics (Basel, Switzerland) · 2026Review
- Enhancing tuberculosis vaccine efficacy with a heterologous mRNA-ChAdOx1 prime-pull strategy targeting lung-resident memory T cells.Frontiers in immunology · 2026Article
- Immune Responsiveness Induced by Administration of Heat-Inactivated M. bovis and BCG Prior to Experimental Infection in African Buffalo.Transboundary and emerging diseases · 2026Article
- Inactivated mycobacterium paragordonae delivered via microneedle patches as a novel tuberculosis booster vaccine.Human vaccines & immunotherapeutics · 2025Article
- A novel nanoparticle vaccine displaying multistage tuberculosis antigens confers protection in mice infected with H37Rv.NPJ vaccines · 2025Article
- New Advances in the Development and Design ofBiology · 2025Review
- Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate.Scientific reports · 2025Article
- Effects of non-tuberculous mycobacteria on BCG vaccine efficacy: A narrative review.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Insights into mycobacteriome composition in Mycobacterium bovis-infected African buffalo (Syncerus caffer) tissue samples.Scientific reports · 2024Article
- An Alarm for Pediatricians Facing BCG Vaccine Complications.Tanaffos · 2024Article
- Mucosal BCG delivery provides a spectrum of protection from differentFrontiers in tuberculosis · 2024Article
- ELISA-R: an R-based method for robust ELISA data analysis.Frontiers in immunology · 2024Article
- Article
- Key advances in vaccine development for tuberculosis-success and challenges.NPJ vaccines · 2023Review
- Protective Effect of BCG and Neutrophil-to-Lymphocyte Ratio on Latent Tuberculosis in End Stage Renal Disease.Infectious diseases and therapy · 2023Article
- Article
- Monoclonal antibodies to lipoarabinomannan/arabinomannan - characteristics and implications for tuberculosis research and diagnostics.Trends in microbiology · 2023Review
- Early-life microbiota-immune homeostasis.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The efficacy of Bacillus Calmette-Guerin (BCG) vaccination in protection against pulmonary tuberculosis (TB) is highly variable between populations. One possible explanation for this variability is increased exposure of certain populations to non-tuberculous mycobacteria (NTM). This study used a murine model to determine the effect that exposure to NTM after BCG vaccination had on the efficacy of BCG against aerosol Mycobacterium tuberculosis challenge. The effects of administering live Mycobacterium avium (MA) by an oral route and killed MA by a systemic route on BCG-induced protection were evaluated. CD4+ and CD8+ T cell responses were profiled to define the immunological mechanisms underlying any effect on BCG efficacy. BCG efficacy was enhanced by exposure to killed MA administered by a systemic route; T helper 1 and T helper 17 responses were associated with increased protection. BCG efficacy was reduced by exposure to live MA administered by the oral route; T helper 2 cells were associated with reduced protection. These findings demonstrate that exposure to NTM can induce opposite effects on BCG efficacy depending on route of exposure and viability of NTM. A reproducible model of NTM exposure would be valuable in the evaluation of novel TB vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.